{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:44:27Z","timestamp":1780098267034,"version":"3.54.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The study aimed to evaluate and compare the leukocyte chemotactic activities of various brimonidine tartrate (BT) eye drop formulations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A 96-well dot-blot platet using a Boyden-style well was used to study the chemotactic effects of BT ophthalmic preparations. A modification was made to create blind wells where the tested agents were placed. Leukocytes were isolated from the peripheral blood of healthy volunteers. As positive controls, we used diluted drugs, benzalkonium chloride solution (BAK), zymosan-activated serum, and formyl-methionine-leucine-phenylalanine peptides. The negative control in our study was a phosphate-buffered saline solution. For each experimental condition, we measured leukocyte migration through a Millipore membrane. The differences in the mean migration distance between groups were compared using the analysis of variance (ANOVA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The measured migration distances (in \u03bcm\u2009\u00b1\u2009SD) were 62.14\u2009\u00b1\u20093.71 for BT 0.2% with BAK (Alcon Laboratories Inc.); 63.61\u2009\u00b1\u20093.81 for BT 0.2% with BAK (Allergan Inc); 40.36\u2009\u00b1\u20093.17 for BT 0.15% without BAK; and 41.02\u2009\u00b1\u20092.17 for BAK alone. The negative controls showed no chemotactic activity, while the positive controls showed the highest neutrophil migration of all experimental conditions. The differences between BT 0.15% without BAK and the other commercial formulations were statistically significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Commercial ophthalmic preparations of BT 0.2% with BAK 0.005% had higher chemotactic properties than the alternative of a lower concentration of BT and without the preservative BAK. Therefore, the latter should be considered for patients with glaucoma or ocular hypertension in order to minimize iatrogenic ocular inflammation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-020-0401-z","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T13:04:09Z","timestamp":1584968649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-8339","authenticated-orcid":false,"given":"Ruiz Simonato","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Parente","family":"Solari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Fran\u00e7a Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Miguel Noel Nascentes","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Palis","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"issue":"1","key":"401_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0149-2918(00)87981-3","volume":"22","author":"S Melamed","year":"2000","unstructured":"Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther. 2000;22(1):103\u201311.","journal-title":"Clin Ther"},{"key":"401_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0039-6257(96)82028-5","volume":"41","author":"TR Walters","year":"1996","unstructured":"Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41:19\u201326.","journal-title":"Surv Ophthalmol"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"CB Toris","year":"1995","unstructured":"Toris CB, Gleaseon ML, Camras CB, Yablonski ME. Effects brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1513\u20137.","journal-title":"Arch Ophthalmol"},{"key":"401_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","volume":"115","author":"JS Schuman","year":"1997","unstructured":"Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice-daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. The Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847\u201352.","journal-title":"Arch Ophthalmol"},{"key":"401_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0149-2918(00)87977-1","volume":"22","author":"DA Lee","year":"2000","unstructured":"Lee DA. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clin Ther. 2000;22:53\u201365.","journal-title":"Clin Ther"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jop.2000.16.3","volume":"16","author":"DA Lee","year":"2000","unstructured":"Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. The Glaucoma Trial Study Group. J Ocul Pharmacol Ther. 2000;16:3\u201318.","journal-title":"J Ocul Pharmacol Ther"},{"key":"401_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0039-6257(96)82029-7","volume":"41","author":"JS Schuman","year":"1996","unstructured":"Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41:27\u2013S37.","journal-title":"Surv Ophthalmol"},{"key":"401_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0039-6257(96)82030-3","volume":"41","author":"JB Serle","year":"1996","unstructured":"Serle JB. A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group. Surv Ophthalmol. 1996;41:39\u2013S47.","journal-title":"Surv Ophthalmol"},{"key":"401_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0002-9394(98)00286-4","volume":"127","author":"LJ Katz","year":"1999","unstructured":"Katz LJ. Brimonidine tartrate 0.2% twice-daily vs. timolol 0.5% twice-daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol. 1999;127:20\u20136.","journal-title":"Am J Ophthalmol"},{"key":"401_CR10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","volume":"105","author":"RP LeBlanc","year":"1998","unstructured":"LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in glaucoma or ocular hypertension. The Brimonidine Study Group. Ophthalmology. 1998;105:1960\u20137.","journal-title":"Ophthalmology"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00061198-200010000-00009","volume":"9","author":"J Javitt","year":"2000","unstructured":"Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II. J Glaucoma. 2000;9:398\u2013408.","journal-title":"J Glaucoma"},{"key":"401_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/archopht.1992.01080160106043","volume":"110","author":"GJ Berdy","year":"1992","unstructured":"Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528\u201332.","journal-title":"Arch Ophthalmol"},{"key":"401_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000055579","volume":"32","author":"PJ Pisella","year":"1992","unstructured":"Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 1992;32:3\u20138.","journal-title":"Ophthalmic Res"},{"key":"401_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0002-9394(74)90016-6","volume":"78","author":"AR Gasset","year":"1974","unstructured":"Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol. 1974;78:98\u2013105.","journal-title":"Am J Ophthalmol"},{"key":"401_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1076\/0271-3683(200002)2021-DFT085","volume":"20","author":"JM De Saint","year":"2000","unstructured":"De Saint JM, Debbasch C, Brignole F, Rat P, Warnet JM, Baoudouin C. Toxicity of preserved and unpreserved glaucoma topical drugs in an in vivo model of conjunctival cells. Curr Eye Res. 2000;20:85\u201394.","journal-title":"Curr Eye Res"},{"key":"401_CR16","first-page":"38","volume":"212","author":"R Grant","year":"1996","unstructured":"Grant R, Ajello M, Vlass E. Salt water or high tech? A look at two new rising solutions for contact lenses. Optician. 1996;212:38\u201341.","journal-title":"Optician"},{"key":"401_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.sjopt.2014.06.006","volume":"28","author":"E Tu","year":"2014","unstructured":"Tu E. Balancing antimicrobial efficacy and toxicity of currently available topical ophthalmic preservatives. Saudi J Ophthalmol. 2014;28:182\u20137.","journal-title":"Saudi J Ophthalmol"},{"key":"401_CR18","volume-title":"Department of Pharmacokinetics and Drug Metabolism","author":"Data on file","year":"1999","unstructured":"Data on file. Department of Pharmacokinetics and Drug Metabolism. Irvine: Allergan; 1999."},{"key":"401_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","volume":"11","author":"LJ Katz","year":"2002","unstructured":"Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119\u201326.","journal-title":"J Glaucoma"},{"key":"401_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/108076803762718097","volume":"19","author":"T Mundorf","year":"2003","unstructured":"Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy ans safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19:37\u201344.","journal-title":"J Ocul Pharmacol Ther"},{"key":"401_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1590\/S0004-27492013000200003","volume":"76","author":"TB Abud","year":"2013","unstructured":"Abud TB, Escuoteguazza Filho M, Oliveira ESS, Abud JF, Prata JA Jr. Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes. Arq Bras Oftalmol. 2013;76:69\u201371.","journal-title":"Arq Bras Oftalmol"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1089\/jop.2007.0042","volume":"23","author":"CY Kim","year":"2007","unstructured":"Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007;23:481\u20136.","journal-title":"J Ocul Pharmacol Ther"},{"key":"401_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","volume":"23","author":"RJ Noecker","year":"2004","unstructured":"Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490\u20136.","journal-title":"Cornea"},{"key":"401_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0002-9394(76)90433-5","volume":"82","author":"JT Patten","year":"1976","unstructured":"Patten JT, Cavanagh HD, Allansmith MR. Induced ocular pseudopenphigoid. Am J Ophthalmol. 1976;82:272\u20136.","journal-title":"Am J Ophthalmol"},{"key":"401_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0161-6420(80)35215-9","volume":"87","author":"EM Van Buskirk","year":"1980","unstructured":"Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology. 1980;87:447\u201350.","journal-title":"Ophthalmology"},{"key":"401_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1076\/ceyr.25.6.363.14232","volume":"25","author":"PC Ozdal","year":"2002","unstructured":"Ozdal PC, Deschen\u00eas J, Rudzinski M, Antecka E, Baines MG. Chemotactic and chemokinetic properties of topical ophthalmic preparations. Curr Eye Res. 2002;25:363\u20138.","journal-title":"Curr Eye Res"},{"key":"401_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0090-1229(87)90014-6","volume":"42","author":"JT Rosenbaum","year":"1987","unstructured":"Rosenbaum JT, Raymond WW, Fujikawa LS, Langois L, Palestine AG, Stamper RL, et al. Chemotactic activity in aqueous humor from patients with anterior uveitis. Clin Immunol Immunopathol. 1987;42:265\u201373.","journal-title":"Clin Immunol Immunopathol"},{"key":"401_CR28","volume-title":"Guidelines for glaucoma eye care","author":"The International Council of Ophthalmology (ICO)","year":"2015","unstructured":"The International Council of Ophthalmology (ICO). Guidelines for glaucoma eye care. 2015. Available at: http:\/\/www.icoph.org\/ICOGlaucomaGuidelines.pdf."},{"issue":"8","key":"401_CR29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1755-3768.2009.01852.x","volume":"89","author":"A Heijl","year":"2011","unstructured":"Heijl A, Leske MC, Hyman L, et al. Intraocular pressure reduction with a fixed treatment protocol in the early manifest glaucoma trial. Acta Ophthalmol. 2011;89(8):749\u201354.","journal-title":"Acta Ophthalmol"},{"key":"401_CR30","volume-title":"Preferred practice pattern\u00ae guidelines","author":"American Academy of Ophthalmology Glaucoma Primary Open Angle Glaucoma Committee","year":"2015","unstructured":"American Academy of Ophthalmology Glaucoma Primary Open Angle Glaucoma Committee. Preferred practice pattern\u00ae guidelines. San Francisco: American Academy of Ophthalmology; 2015. Available at: www.aao.org\/ppp."},{"key":"401_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000266250","volume":"20","author":"E Tsai","year":"1988","unstructured":"Tsai E, Till GO, Marak GE. Effects of mydriatic agents on neutrophil migration. Ophthalmic Res. 1988;20:14\u20139.","journal-title":"Ophthalmic Res"},{"issue":"2","key":"401_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/09273948.2015.1037845","volume":"24","author":"J Beltz","year":"2016","unstructured":"Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24(2):128\u201333.","journal-title":"Ocul Immunol Inflamm"},{"key":"401_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0002-9394(00)00491-8","volume":"130","author":"DB Byles","year":"2000","unstructured":"Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130:287\u201391.","journal-title":"Am J Ophthalmol"},{"key":"401_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/eye.2000.250","volume":"14","author":"R Goyal","year":"2000","unstructured":"Goyal R, Ram AR. Brimonidine tartrate 0.2% (Alphagan) associated granulomatous anterior uveitis. Eye. 2000;14:908\u201310.","journal-title":"Eye"},{"key":"401_CR35","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/archopht.122.7.1063","volume":"122","author":"HI Becker","year":"2004","unstructured":"Becker HI, Walton RC, Diamant JI, Zegans ME. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol. 2004;122:1063\u20136.","journal-title":"Arch Ophthalmol"},{"key":"401_CR36","first-page":"1967","volume":"8","author":"A Alm","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967\u201385.","journal-title":"Clin Ophthalmol"},{"key":"401_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2016.06.135","volume":"511","author":"JJ Hakkarainen","year":"2016","unstructured":"Hakkarainen JJ, Reinisalo M, Ragauskas S, Seppanen A, Kaja S, Kalesnylas G. Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. Int J Pharm. 2016;511:73\u20138.","journal-title":"Int J Pharm"},{"key":"401_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2016.06.014","volume":"788","author":"A Trezeciecka","year":"2016","unstructured":"Trezeciecka A, Paterno JJ, Toropainen E, Koskela A, Podracka L, Korhonen E, et al. Long-term topical application of preservative prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016;788:12\u201320.","journal-title":"Eur J Pharmacol"},{"key":"401_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17469899.4.1.59","volume":"4","author":"PD Freeman","year":"2009","unstructured":"Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2009;4:59\u201364.","journal-title":"Expert Rev Ophthalmol"},{"key":"401_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/archopht.122.7.1019","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, Wolfs RC, O\u2019Colmain BJ, Klein BE, Taylor HR, West S, et al. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532\u20138.","journal-title":"Arch Ophthalmol"},{"key":"401_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","volume":"136","author":"DA Schaumberg","year":"2003","unstructured":"Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318\u201326.","journal-title":"Am J Ophthalmol"},{"key":"401_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","volume":"127","author":"DA Schaumberg","year":"2009","unstructured":"Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physician\u2019s Health Studies. Arch Ophthalmol. 2009;127:763\u20138.","journal-title":"Arch Ophthalmol"},{"key":"401_CR43","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e8 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"401_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000334791","volume":"50","author":"C Baudoin","year":"2012","unstructured":"Baudoin C. Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2012;50:64\u201378.","journal-title":"Dev Ophthalmol"},{"key":"401_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000458487","volume":"59","author":"C Baudoin","year":"2017","unstructured":"Baudoin C. Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2017;59:67\u201379.","journal-title":"Dev Ophthalmol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0401-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-0401-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0401-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:12:40Z","timestamp":1616458360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-0401-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-0401-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written authorization in the consent form was obtained to collect a blood sample from healthy volunteers. The entire procedure was authorized by the university\u2019s research ethics committee (CEP) and by the national research commission (CONEP) under registration number 1.466.576.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}